IMV Inc. Provides Clinical and Operational Update and Announces First Quarter 2020 Financial Results
IMV Inc. Establishes At-the-Market Facility
Micro-cap Canadian biopharma Imv Inc (NASDAQ: IMV) said Wednesday that it is advancing the clinical development of a DPX-based vaccine candidate for the coronavirus, joining a number of biotechs working on the virus as the world grapples with a pandemic. The development program will establish the safety and immunogenicity of a vaccine candidate based on the company's DPX delivery technology that incorporates peptides targeting novel epitopes from the new coronavirus strain, IMV said in a press release. DPX is IMV's proprietary lipid-based delivery platform that requires no aqueous component. It can be formulated with peptide antigens.Its unique "no release" mechanism of action allows antigen presenting cells to be attracted to the injection site, facilitating a robust and sustained immune response within lymph nodes, according to IMV. "We believe this technology offers a meaningful solution as a potential vaccine, especially in older adults and those with pre-existing conditions who are most at risk to this virus and generally more difficult to vaccinate effectively," CEO Frederic Ors said in a statement. IMV said it intends to develop DPX-COVID-19 in collaboration with lead investigators for the Phase 1 clinical study of DPX-RSV, who will assist with preclinical and clinical evaluation and further development in collaboration with the Canadian government and others.The company said its investigational asset DPX-RSV demonstrated a favorable safety profile and immunogenicity in older adults in a Phase 1 study. It has also reported preclinical data from several candidates targeting other infectious diseases such as malaria and anthrax.The stock was trading 33.25% higher at $2.70 at the time of publication. Related Links:The Daily Biotech Pulse: AbbVie, Allergan Agree On Divestments, Obalon Stops Obesity Balloon Sale, COVID-19 Updates 10 Small-To-Mid-Cap Biotech Ideas For When The Coronavirus FadesSee more from Benzinga * The Daily Biotech Pulse: AbbVie, Allergan Agree On Divestments, Obalon Stops Obesity Balloon Sale, COVID-19 Updates * The Daily Biotech Pulse: GenMark Diagnostics Ships COVID-19 Test Kits, Karyopharm To Offer Shares, And More * The Daily Biotech Pulse: Moderna Ships COVID-19 Vaccine For Clinics, Mallinckrodt Strikes .6B Opioid Settlement(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Two coronavirus vaccine candidates are in the clinics and 42 more are in preclinical studies, according to updated data provided by the World Health Organization on March 20.Three biopharma companies issued updates Monday on their developmental efforts for vaccines to combat the deadly virus, which has so far killed more than 35,000 people and infected about 735,000 more, according to Johns Hopkins University. IMV On Track For Summer Start Canadian pharma Imv Inc (NASDAQ: IMV), which announced March 18 its intention to develop a DPX-based vaccine candidate for the new coronavirus, said it has initiated discussions with Health Canada to prepare for a clinical trial application. Using the genomic and proteomic sequences of the novel coronavirus, the company said it identified several hundred epitopes and shortlisted 23 based on their biological relevance to the virus and potential to generate neutralizing antibodies. IMV said it has begun manufacturing peptide candidates targeting these epitopes, and said it is in talks with suppliers and contract manufacturers to prepare for the cGMP batch required to support a clinical study.The company has finalized the design of a planned Phase 1 study in 48 healthy subjects and identified clinical sites in Nova Scotia and Quebec, according to a press release. IMV said it is scheduled to meet with regulators in the week of April 20, with a goal of beginning clinical testing in summer 2020. It also said it has submitted several grant applications in Canada to help support the program."We remain committed to serving the unmet needs of patients, both through our efforts to potentially develop a prophylactic vaccine to curb this novel coronavirus and across our ongoing clinical studies with DPX-Survivac in advanced-stage cancer patients," CEO Frederic Ors said in a statement. See also: Novavax Shares Rally On Flu Vaccine Study Results: What You Need To Know Benzinga is covering every angle of how the coronavirus affects the financial world. For daily updates, sign up for our coronavirus newsletter.Altimmune To Work With University of Alabama On Intranasal Vaccine Altimmune Inc (NASDAQ: ALT) said it has launched a collaboration with the University of Alabama at Birmingham for developing a single-dose, intranasal COVID-19 vaccine, AdCOVID.The company said it is preparing for immunogenicity studies and manufacturing of Phase 1 trial material. Altimmune said it will work with university investigators on preclinical animal studies and characterization of vaccine immunogenicity. The company is planning a Phase 1 study in the third quarter.J&J Plans Clinical Testing By September, Commits Over $1B In Funding Johnson & Johnson (NYSE: JNJ) said it has selected a lead COVID-19 vaccine candidate from constructs it has been working on since January.The company said that, through a new partnership with the BARDA, it has committed more than $1 billion to co-fund vaccine research, development and clinical testing.Separately, the company and BARDA have provided additional funding to enable expansion of their ongoing work to identify potential treatments for the virus.Additionally, J&J said it is expanding its global manufacturing capacity to assist in the rapid production of a vaccine and supply of more than 1 billion doses of a safe and effective vaccine globally.J&J said it is "committed to bringing an affordable vaccine to the public on a not-for-profit basis for emergency pandemic use."J&J expects to initiate human clinical studies at the latest by September 2020 and make available the first batch of a vaccine for emergency use authorization in early 2021.At the time of publication Monday: * Altimmune shares were rising 2.1% to $2.91. * IMV was gaining 6.06% to $1.75. * J&J shares were adding 5.44% to $129.86.See more from Benzinga * The Daily Biotech Pulse: Milestone Pharma Flunks Late-Stage Study, CytomX Strikes Cancer Drug Collaboration, BARDA Grant For GenMark's COVID-19 Test * The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latestage Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection * 8 Biotechs With Coronavirus Vaccines In Development(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Cheap stocks - that is, really cheap stocks that trade for single-digit prices - are among the most divisive stocks on Wall Street.Some investors tend to avoid these names entirely. While nominal prices typically don't matter (there's little difference between a $50 stock and a $500 stock), stocks under $10 are different. They often face some sort of difficulty, such as weak fundamentals or overwhelming headwinds. Also, institutional buyers such as pensions and hedge funds often won't buy stocks that are cheaper than $10, and they really become sparse under the $5 mark. Thus, these companies miss out on the steadiness that accompanies institutional ownership.But other investors love cheap stocks. In many cases, they see opportunity in these often battered shares, and some people simply prefer to buy their stocks in "lots" (typically 100 shares at a time) - something that's a little more difficult to do with the triple- and quadruple-digit crowd.The reality is, low-priced stocks are a mix of high-return opportunity but also high risk. The crazy volatility introduced by the coronavirus outbreak certainly doesn't help. Further complicating things is that many of them are largely ignored by the media, making information difficult to come by. So if you are going to take a moonshot, take a cue from the pros that routinely cover these companies.Here are seven of the best cheap stocks under $7. Using TipRanks' Stock Screener tool, we identified seven low-priced stocks that still have decent Wall Street analyst coverage and extremely bullish sentiment. Note that every one of these stocks still comes with colossal risk. But if you're looking to get aggressive and buy cheap on dips, the pros think each of these can offer some promise. SEE ALSO: 13 Super Small-Cap Stocks to Buy for 2020 and Beyond
IMV INC (IMV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
IMV INC. ANNOUNCES CLOSING OF $25.1 MILLION PRIVATE PLACEMENT
IMV Inc. to Announce First Quarter 2020 Results and Host a Conference Call and Webcast on May 15, 2020
IMV Announces Proposed $22.3 Million Private Placement
IMV plans to develop a vaccine candidate using its lipid-based delivery platform, DPX technology, for the treatment of coronavirus disease. Stock rises.
IMV INC (IMV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
IMV INC (IMV) delivered earnings and revenue surprises of -27.27% and 27.50%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
A co‑lead investor with Lumira Ventures in this financing round, the Fonds has been a partner of IMV since February 2018 . IMV, whose management team is based in Québec, is currently working on a vaccine candidate against COVID-19.
IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company (the "Company" or "IMV"), today announced that it is advancing the clinical development of a DPX-based vaccine candidate against COVID-19. Vaccines against infectious disease have been a core part of IMV’s heritage across its DPX platform technology.
IMV to Announce Fourth Quarter and Full Year 2019 Financial and Operational Results and Host Investor Conference Call and Webcast on March 31, 2020
IMV Inc. Announces Fourth Quarter and Full Year 2019 Financial and Operational Results
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines against infectious diseases, today announced positive preclinical results demonstrating robust immunogenic and antibody responses from the majority of peptide epitopes. Based on these data, the Company has selected multiple peptide epitopes to be formulated within its DPX platform to form a vaccine candidate against the novel coronavirus, DPX-COVID-19.
IMV to participate in Adelaide Capital’s Virtual COVID & Healthcare Mini Conference
IMV Inc. (Nasdaq: IMV) (TSX: IMV), a clinical-stage biopharmaceutical company (the "Company" or "IMV"), today provided updates on the development of DPX-COVID-19, a vaccine candidate against the novel coronavirus, and on the Company’s business and clinical operations amid the COVID-19 pandemic.